Timing of Treatment Completion in Staged Selective Laser Trabeculoplasty (SLT): Early vs. Late Completion - Full Text View

Sponsored by:	Queen's University
Information provided by:	Queen's University
ClinicalTrials.gov Identifier:	NCT00551395

Purpose

This study will evaluate the effect of the timing of treatment completion in two-staged selective laser trabeculoplasty therapy on intraocular pressure lowering effect.

Condition	Intervention	Phase
Glaucoma	Procedure: selective laser trabeculoplasty - early completion Procedure: Selective laser trabeculoplasty - late completion	Phase III

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study
Official Title:	Timing of Treatment Completion in Staged Selective Laser Trabeculoplasty (SLT): Early vs. Late Completion

Further study details as provided by Queen's University:

Primary Outcome Measures:

intraocular pressure lowering [ Time Frame: 1 month following procedure ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

intraocular pressure lowering [ Time Frame: 3, 6, 12 and 24 months following procedure ] [ Designated as safety issue: Yes ]

Enrollment:	20
Study Start Date:	September 2007
Estimated Study Completion Date:	January 2009
Estimated Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Early Completion	Procedure: selective laser trabeculoplasty - early completion 180 degrees of laser on day 1 and other 180 degrees on day 2.
2: Active Comparator Late Completion	Procedure: Selective laser trabeculoplasty - late completion 180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 years of age
primary open angle glaucoma or pseudoexfoliation glaucoma

Exclusion Criteria:

Unable to give informed consent

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00551395

Locations

Canada, Ontario
Hotel Dieu Hospital & Queen's University
Kingston, Ontario, Canada, K7L 5G2

Sponsors and Collaborators

Queen's University

Investigators

Principal Investigator:

Robert J Campbell, MD

Queen's University, Kingston, Canada

More Information

Responsible Party:	Queen's University ( Dr. Robert J. Campbell )
Study ID Numbers:	RC-1
Study First Received:	October 29, 2007
Last Updated:	January 14, 2009
ClinicalTrials.gov Identifier:	NCT00551395
Health Authority:	Canada: Ethics Review Committee

Keywords provided by Queen's University:

glaucoma
laser
trabeculoplasty

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on January 15, 2009